Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Savings From Part B Rx Price Substitution Are Small, But Worth Getting – OIG

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Office of Inspector General says CMS’ price substitution policy for drugs exceeding 5% in ASP/AMP pricing differential would have saved Medicare $7 million in 2011, less than a tenth of a percent of total Part B drug spending, CMS does not concur with OIG recommendations to help increase savings.

You may also be interested in...



CMS Resists OIG Pressure To Expand Drug Price Substitution In Medicare

CMS does not concur with recommendations from the HHS Office of the Inspector General that it should apply its AMP-based price substitution more broadly for drugs reimbursed by Medicare Part B.

“Bona Fide Service Fees” Lawsuit Underscores Need For Care In Distributor Contracts, Medicaid AMP Calculations

Litigation being pursued by former drug wholesale association exec alleges that manufacturers inappropriately classed bona fide service fees as discounts, causing them to report inaccurate average manufacturer prices to CMS.

Medicare Drug Price Substitution For Part B Proposed Again By CMS

The proposal to reimburse less for drugs that exceed a price substitution threshold, first made last year but never finalized, is part of the Physician Fee Schedule proposed rule for 2012.

Topics

UsernamePublicRestriction

Register

PS075322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel